X4 Pharmaceuticals, Inc SEC filings XFOR
X4 Pharmaceuticals, Inc has 818 filings in SEC EDGAR's recent list, going back to Sep 24, 2010. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 20, 2026 | — |
| DEF 14A | Proxy statement | Mar 20, 2026 | Mar 20, 2026 |
| DEF 14A | Proxy statement | Apr 25, 2025 | Apr 25, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Mar 24, 2025 | Mar 24, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 14, 2025 | Mar 14, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 25, 2023 | Apr 25, 2023 |
| DEF 14A | Proxy statement | Aug 11, 2022 | Sep 1, 2022 |
| PRE 14A | Preliminary proxy statement | Aug 1, 2022 | Sep 1, 2022 |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 6, 2022 |
| DEFA14A | Additional proxy material | Apr 20, 2021 | — |
| DEF 14A | Proxy statement | Apr 20, 2021 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | May 12, 2020 | — |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 10, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2020 | Jun 10, 2020 |
| DEF 14A | Proxy statement | May 22, 2019 | Jun 17, 2019 |
| DEFA14A | Additional proxy material | Mar 8, 2019 | — |
| DEFA14A | Additional proxy material | Mar 1, 2019 | — |
| DEF 14A | Proxy statement | Apr 23, 2018 | Jun 5, 2018 |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- XFOR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1501697
- Former names
- Arsanis, Inc. (until Mar 13, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.